LabConnect Partners with The Bracken Group to Enhance Radiopharmaceutical Support Services
In a significant move, LabConnect, a leading provider of central lab services and support for clinical trials, has announced a strategic partnership with The Bracken Group. This collaboration aims to enhance LabConnect's capabilities in the growing sector of radiopharmacy.
As the demand for radiopharmacy expertise continues to rise—projected to grow annually by 15 to 20 percent—LabConnect is poised to better serve clients in the biopharmaceutical arena developing targeted treatments and diagnostics. The Bracken Group, recognized as a leader in radiopharmacy advisory, brings extensive scientific knowledge and a comprehensive approach to the market, focusing on development, regulatory frameworks, and commercialization processes.
Wes Wheeler, the CEO of LabConnect, expressed the potential this partnership holds, stating, "This collaboration provides us with a unique opportunity to blend operational excellence with deep scientific expertise." He further emphasized that Bracken's expertise will strengthen LabConnect's ability to navigate the complex logistical and analytical challenges inherent in radiopharmaceutical trials.
Colin Miller, PhD, CEO of Bracken Consulting, shared similar sentiments: "LabConnect’s commitment to innovation aligns seamlessly with Bracken's mission. Together, we bridge the gap between medicine, science, and practical operations in a way unmatched in our industry." He reiterated that Bracken is a global leader in radiopharmaceutical development consulting, from preclinical phases to market strategies. By partnering with LabConnect, they have the opportunity to elevate their services and establish LabConnect as a premier partner for clients involved in the development of radiopharmaceutical products, whether for diagnostics or radioligand therapies (RLT).
The partnership will focus on enhancing service delivery in crucial areas such as sample processing, logistics, and scientific oversight—elements vital to the high-stakes, highly regulated environment of radiopharmacy.
About LabConnect
LabConnect, LLC is recognized as a principal provider of central laboratory services, FSP, and scientific consulting, alongside integration and data transformation services for complex analytical and logistical studies, including immuno-oncology, cellular and gene therapies, and rare diseases. By combining cutting-edge technology with world-class laboratories and extensive specialized trial expertise, LabConnect serves as a one-stop provider for central laboratory service needs for drug development companies.
To learn more, visit www.labconnect.com and follow the company on LinkedIn.
About Bracken
The Bracken Group provides consulting, regulatory, analytics, marketing, and sales activation solutions for the life sciences and digital health industries. Through highly experienced consultative support, business programs, and data-driven products, Bracken adopts a multidisciplinary approach to exceed client objectives.
For more information, check out www.thebrackengroup.com and follow their LinkedIn page.
As the demand for radiopharmacy expertise continues to rise—projected to grow annually by 15 to 20 percent—LabConnect is poised to better serve clients in the biopharmaceutical arena developing targeted treatments and diagnostics. The Bracken Group, recognized as a leader in radiopharmacy advisory, brings extensive scientific knowledge and a comprehensive approach to the market, focusing on development, regulatory frameworks, and commercialization processes.
Wes Wheeler, the CEO of LabConnect, expressed the potential this partnership holds, stating, "This collaboration provides us with a unique opportunity to blend operational excellence with deep scientific expertise." He further emphasized that Bracken's expertise will strengthen LabConnect's ability to navigate the complex logistical and analytical challenges inherent in radiopharmaceutical trials.
Colin Miller, PhD, CEO of Bracken Consulting, shared similar sentiments: "LabConnect’s commitment to innovation aligns seamlessly with Bracken's mission. Together, we bridge the gap between medicine, science, and practical operations in a way unmatched in our industry." He reiterated that Bracken is a global leader in radiopharmaceutical development consulting, from preclinical phases to market strategies. By partnering with LabConnect, they have the opportunity to elevate their services and establish LabConnect as a premier partner for clients involved in the development of radiopharmaceutical products, whether for diagnostics or radioligand therapies (RLT).
The partnership will focus on enhancing service delivery in crucial areas such as sample processing, logistics, and scientific oversight—elements vital to the high-stakes, highly regulated environment of radiopharmacy.
About LabConnect
LabConnect, LLC is recognized as a principal provider of central laboratory services, FSP, and scientific consulting, alongside integration and data transformation services for complex analytical and logistical studies, including immuno-oncology, cellular and gene therapies, and rare diseases. By combining cutting-edge technology with world-class laboratories and extensive specialized trial expertise, LabConnect serves as a one-stop provider for central laboratory service needs for drug development companies.
To learn more, visit www.labconnect.com and follow the company on LinkedIn.
About Bracken
The Bracken Group provides consulting, regulatory, analytics, marketing, and sales activation solutions for the life sciences and digital health industries. Through highly experienced consultative support, business programs, and data-driven products, Bracken adopts a multidisciplinary approach to exceed client objectives.
For more information, check out www.thebrackengroup.com and follow their LinkedIn page.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.